Apellis Pharmaceuticals, Inc. (APLS) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Apellis Pharmaceuticals, Inc. (APLS) Bundle
Evaluate the financial prospects of Apellis Pharmaceuticals, Inc. (APLS) like an expert! This (APLS) DCF Calculator provides pre-filled financial data and full flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 250.6 | 66.6 | 75.4 | 396.6 | 436.1 | 479.6 | 527.4 | 579.9 | 637.7 |
| Revenue Growth, % | 0 | 0 | -73.44 | 13.31 | 425.83 | 9.97 | 9.97 | 9.97 | 9.97 | 9.97 |
| EBITDA | -298.8 | -312.2 | -731.3 | -617.4 | -495.2 | -261.7 | -287.7 | -316.4 | -348.0 | -382.6 |
| EBITDA, % | 100 | -124.57 | -1098.61 | -818.58 | -124.87 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .6 | .9 | 1.5 | 1.5 | 1.7 | 91.6 | 100.7 | 110.7 | 121.8 | 133.9 |
| Depreciation, % | 100 | 0.34271 | 2.24 | 1.97 | 0.42966 | 21 | 21 | 21 | 21 | 21 |
| EBIT | -299.4 | -313.1 | -732.8 | -618.9 | -496.9 | -261.7 | -287.7 | -316.4 | -348.0 | -382.6 |
| EBIT, % | 100 | -124.91 | -1100.85 | -820.55 | -125.3 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 352.0 | 877.6 | 700.6 | 551.8 | 352.3 | 426.4 | 468.9 | 515.6 | 567.0 | 623.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 25.0 | 10.1 | 7.7 | 206.4 | 163.5 | 179.8 | 197.7 | 217.4 | 239.1 |
| Account Receivables, % | 100 | 9.97 | 15.18 | 10.25 | 52.05 | 37.49 | 37.49 | 37.49 | 37.49 | 37.49 |
| Inventories | .0 | .0 | 16.3 | 85.7 | 146.4 | 228.0 | 250.7 | 275.7 | 303.2 | 333.4 |
| Inventories, % | 100 | 0.000000399 | 24.47 | 113.65 | 36.91 | 52.27 | 52.27 | 52.27 | 52.27 | 52.27 |
| Accounts Payable | 8.4 | 8.5 | 16.9 | 37.3 | 37.5 | 163.8 | 180.1 | 198.0 | 217.8 | 239.5 |
| Accounts Payable, % | 100 | 3.38 | 25.4 | 49.51 | 9.46 | 37.55 | 37.55 | 37.55 | 37.55 | 37.55 |
| Capital Expenditure | -1.7 | -5.4 | -1.1 | -1.5 | -.8 | -5.3 | -5.8 | -6.4 | -7.0 | -7.7 |
| Capital Expenditure, % | 100 | -2.16 | -1.66 | -2.02 | -0.19491 | -1.21 | -1.21 | -1.21 | -1.21 | -1.21 |
| Tax Rate, % | -0.40494 | -0.40494 | -0.40494 | -0.40494 | -0.40494 | -0.40494 | -0.40494 | -0.40494 | -0.40494 | -0.40494 |
| EBITAT | -304.4 | -314.8 | -733.1 | -619.5 | -498.9 | -261.7 | -287.7 | -316.4 | -348.0 | -382.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -297.2 | -344.2 | -725.7 | -666.2 | -757.2 | -87.8 | -215.5 | -237.0 | -260.6 | -286.6 |
| WACC, % | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -814.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -292 | |||||||||
| Terminal Value | -4,149 | |||||||||
| Present Terminal Value | -2,691 | |||||||||
| Enterprise Value | -3,506 | |||||||||
| Net Debt | -240 | |||||||||
| Equity Value | -3,265 | |||||||||
| Diluted Shares Outstanding, MM | 119 | |||||||||
| Equity Value Per Share | -27.51 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real APLS financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Apellis Pharmaceuticals’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Financial Data: Gain access to precise historical performance and future outlooks for Apellis Pharmaceuticals, Inc. (APLS).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Instantaneous updates to DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries to effectively illustrate your valuation findings.
- Suitable for All Experience Levels: Designed for investors, CFOs, and consultants alike, with an easy-to-navigate format.
How It Works
- 1. Access the Template: Download and open the Excel file containing Apellis Pharmaceuticals, Inc. (APLS) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures to fit your analysis.
- 3. Analyze Results Immediately: The DCF model automatically calculates the intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate various forecasts to examine different valuation scenarios.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making process.
Why Choose Apellis Pharmaceuticals, Inc. (APLS)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Expertise: A team of industry leaders committed to advancing healthcare.
- Patient-Centric Approach: Focused on improving patient outcomes through targeted treatments.
- Robust Pipeline: A diverse range of products in development to tackle various conditions.
- Strong Commitment to Research: Ongoing investment in research and development to drive innovation.
Who Should Use This Product?
- Pharmaceutical Students: Understand drug development processes and apply them using real case studies.
- Researchers: Integrate advanced modeling into your studies or clinical research.
- Investors: Evaluate your investment strategies and analyze the performance of Apellis Pharmaceuticals (APLS).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biopharmaceuticals.
- Healthcare Professionals: Learn how companies like Apellis are evaluated in the context of market trends.
What the Template Contains
- Preloaded APLS Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.